CGRP vs Glutathione

Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.

CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene, expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature, where it functions as a potent vasodilator and pain neuromodulator central to migraine pathophysiology. CGRP activates its receptor complex (CLR/RAMP1) to mediate vasodilation and nociceptive signal amplification; during migraine attacks, trigeminal activation releases CGRP at elevated plasma concentrations, and blockade of this pathway has been established as the primary validated pharmacological target for modern preventive migraine therapy. Phase 3 randomized controlled trials published in the New England Journal of Medicine and the Lancet — including the STRIVE trial (Goadsby et al. 2017) and a Phase 3b study in treatment-refractory patients — demonstrated that anti-CGRP monoclonal antibodies significantly reduced monthly migraine days versus placebo, validating the pathway and supporting FDA approval of erenumab, fremanezumab, and galcanezumab. CGRP itself is an endogenous neuropeptide and is not a therapeutic agent that is compounded or administered by providers; the FDA-approved interventions are monoclonal antibody and small-molecule receptor antagonists available by prescription, and exogenous CGRP peptide is exclusively a research tool compound used in vasodilatory and pain signaling pharmacology studies.

Master endogenous antioxidant tripeptide; neutralizes ROS, regenerates vitamins C and E, supports phase II liver detoxification, maintains intracellular redox balance

Glutathione (γ-glutamyl-cysteinyl-glycine, GSH) is the most abundant endogenous intracellular antioxidant tripeptide, synthesized from cysteine, glutamate, and glycine in virtually all mammalian cells, where it maintains redox homeostasis by scavenging reactive oxygen species, regenerating oxidized vitamins C and E, and serving as substrate for glutathione peroxidase and glutathione S-transferase detoxification pathways. Cysteine availability is the rate-limiting step in GSH synthesis, and depletion of glutathione is a consistent feature of neurodegenerative conditions including Parkinson's disease substantia nigra, where oxidative stress plays a central role in dopaminergic neuronal injury. A randomized, double-blind pilot trial published in Movement Disorders evaluated intravenous glutathione in Parkinson's disease patients; separately, a pharmacokinetic study established that orally ingested glutathione is not systemically bioavailable — failing to raise plasma or erythrocyte GSH levels — which defines the rationale for parenteral and liposomal delivery formulations. Glutathione is available as a compounded injectable preparation and as an oral dietary supplement, but it has no FDA approval for any clinical indication; IV glutathione is administered off-label in integrative settings with an evidence base insufficient to establish efficacy for any specific condition, and claims regarding its use for general wellness or skin lightening lack rigorous clinical support. IV glutathione therapy: intravenous glutathione is offered at integrative medicine clinics, IV therapy lounges, and some telehealth platforms as part of NAD+ IV drips, wellness protocols, or standalone antioxidant infusions. Common clinical doses studied range from 600 mg to 1,200 mg IV per session. IV administration bypasses the oral bioavailability problem and raises plasma glutathione levels acutely, though the clinical significance of this acute elevation for most wellness endpoints remains unestablished in controlled trials. Glutathione IV drips are frequently paired with NAD+ infusions given overlapping antioxidant and mitochondrial support rationales in integrative clinical practice. Glutathione for skin: glutathione has been studied in clinical settings for its melanin-inhibiting properties — specifically, its ability to shift melanin synthesis from eumelanin (darker) toward phaeomelanin (lighter pigmentation) via tyrosinase pathway inhibition. Several small RCTs from Asian clinical centers have examined IV and oral glutathione for skin lightening, with mixed results; the evidence base is not sufficient for regulatory approval in any jurisdiction, and high-dose IV glutathione for cosmetic pigmentation is controversial from a safety standpoint in medical literature. N-acetylcysteine (NAC) is a glutathione precursor with superior oral bioavailability and its own independent research base; it is often preferred for systemic antioxidant applications. Providers offering IV glutathione as part of wellness protocols are listed in the PeptideBase directory.